Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. eHealth-mind the gap

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Monocular and binocular end-points after epiretinal membrane surgery and their correlation to patient-reported outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The tolerance of anisometropia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Isolated Ocular Sarcoidosis Mimicking Ring Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Purpose: Ruthenium-106 (Ru-106) brachytherapy is a common eye-preserving treatment for choroidal melanomas. However, a dose-response model describing the relationship between the actual delivered tumour dose and tumour control has, to the best of our knowledge, not previously been quantified for Ru-106 brachytherapy; we aimed to rectify this.Material and methods: We considered consecutive patients with primary choroidal melanomas, treated with Ru-106 brachytherapy (2005-2014). Dosimetric plans were retrospectively recreated using 3D image-guided planning software. Pre-treatment fundus photographies were used to contour the tumour; post-treatment photographies to determine the accurate plaque position. Patient and tumour characteristics, treatment details, dose volume histograms, and clinical outcomes were extracted. Median follow-up was 5.0 years. The relationship between tumour dose and risk of local recurrence was examined using multivariate Cox regression modelling, with minimum physical tumour dose (D99%) as primary dose metric.Results: We included 227 patients with median tumour height and largest base dimension of 4 mm (range 1-12, IQR 3-6) and 11 mm (range 4-23, IQR 9-13). The estimated 3 year local control was 82% (95% CI 77-88). Median D99% was 105 Gy (range 6-783, IQR 65-138); this was the most significant factor associated with recurrence (p < .0001), although tumour height, combined TTT and Ru-106 brachytherapy, and sex were also significant. The hazard ratio (HR) for a 10 Gy increase in D99% was 0.87 (95% CI 0.82-0.93). Using biological effective dose in the model resulted in no substantial difference in dose dependence estimates. Robustness cheques with D1-99% showed D99% to be the most significant dose metric for local recurrence.Conclusion: The minimum tumour dose correlated strongly with risk of tumour recurrence, with 100 Gy needed to ensure at least 84% local control at 3 years.

OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind59
Udgave nummer8
Sider (fra-til)918-925
Antal sider8
ISSN0284-186X
DOI
StatusUdgivet - aug. 2020

ID: 59852863